Garetosmab
Sponsors
Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals
Conditions
Fibrodyplasia Ossificans Progressiva (FOP)Fibrodysplasia Ossificans ProgressivaFibrodysplasia Ossificans Progressiva (FOP)Heterotopic Ossification (HO)Obesity
Phase 1
Phase 2
Phase 3
Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)
WithdrawnNCT04577820
Start: 2021-10-13End: 2022-10-08Updated: 2021-11-01
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Active, not recruitingNCT05394116
Start: 2022-11-21End: 2029-02-27Updated: 2026-07-17
Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability and Efficacy of Garetosmab in Patients with Fibrodysplasia Ossificans Progressiva
Active, not recruitingCTIS2023-508350-26-00
Start: 2023-03-02Target: 24Updated: 2025-09-17
A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)
Not yet recruitingNCT07559513
Start: 2027-02-02End: 2029-12-21Target: 18Updated: 2026-08-24